In particular, narrow gaps among ECM hinder nanomedicine from penetrating away from blood vessels to tumor interior, leading to heterogeneous distribution around blood vessels and limited antitumor efficacy.[5] Therefore, depletion of CAFs and degradation of ECM were key approaches to removal of obstacles for effective tumor penetration and antitumor efficacy. This evidence concerns the gene TBX1 and neoplasm.